# Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

> **NCT02121990** · PHASE1 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 17 (actual)

## Conditions studied

- Ovarian Cancer
- Primary Peritoneal Cancer
- Fallopian Tube Cancer

## Interventions

- **DRUG:** Paclitaxel,
- **DRUG:** Bevacizumab
- **DRUG:** Cisplatin
- **DRUG:** Olaparib

## Key facts

- **NCT ID:** NCT02121990
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04-21
- **Primary completion:** 2020-08-19
- **Final completion:** 2020-08-19
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2020-08-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02121990

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02121990, "Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02121990. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*